Methysergide
Sansert (methysergide) is a small molecule pharmaceutical. Methysergide was first approved as Sansert on 1982-01-01. It is used to treat vascular headaches in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C and 5-hydroxytryptamine receptor 2B. In addition, it is known to target 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1E, and 5-hydroxytryptamine receptor 1F.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methysergide maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SANSERT | Novartis | N-012516 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| vascular headaches | — | D014653 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
53 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Constipation | D003248 | HP_0002019 | K59.0 | — | 2 | 4 | 3 | 1 | 10 |
| Opioid-induced constipation | D000079689 | — | 2 | 3 | 3 | 1 | 8 | ||
| St elevation myocardial infarction | D000072657 | — | — | — | 1 | — | 1 | ||
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 2 | — | — | 2 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | 1 | 1 | — | — | 1 |
| Enteral nutrition | D004750 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | 1 | — | — | — | 5 | ||
| Gastroparesis | D018589 | EFO_1000948 | K31.84 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intestinal obstruction | D007415 | K56.60 | 2 | — | — | — | — | 2 | |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHYSERGIDE |
| INN | methysergide |
| Description | (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide is an ergoline alkaloid. |
| Classification | Small molecule |
| Drug class | ergot alkaloid deriviatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCC(CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1 |
Identifiers
| PDB | — |
| CAS-ID | 361-37-5 |
| RxCUI | 6911 |
| ChEMBL ID | CHEMBL485253 |
| ChEBI ID | 584020 |
| PubChem CID | 9681 |
| DrugBank | DB00247 |
| UNII ID | XZA9HY6Z98 (ChemIDplus, GSRS) |
Target
Agency Approved
HTR2C
HTR2C
HTR2B
HTR2B
Organism
Homo sapiens
Gene name
HTR2C
Gene synonyms
HTR1C
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2C
Protein synonyms
5-HT-1C, 5-HT1C, 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled, 5-hydroxytryptamine receptor 1C, serotonin 5-HT-1C receptor, serotonin 5-HT-2C receptor, Serotonin receptor 2C
Uniprot ID
Mouse ortholog
Htr2c (15560)
5-hydroxytryptamine receptor 2C (Q5WRU6)
Alternate
HTR1B
HTR1B
HTR6
HTR6
HTR5A
HTR5A
HTR1D
HTR1D
HTR2A
HTR2A
HTR7
HTR7
HTR1E
HTR1E
HTR1F
HTR1F
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,758 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
934 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more